Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
- PMID: 32642965
- PMCID: PMC7340862
- DOI: 10.1007/s12325-020-01419-6
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
Abstract
Introduction: Chemotherapy-induced myelosuppression (CIM) is one of the most common dose-limiting complications of cancer treatment, and is associated with a range of debilitating symptoms that can significantly impact patients' quality of life. The purpose of this study was to understand patients' perspectives on how the side effects of CIM are managed in routine clinical practice.
Methods: An online survey was conducted of participants with breast, lung, or colorectal cancer who had received chemotherapy treatment within the past 12 months, and had experienced at least one episode of myelosuppression in the past year. The survey was administered with predominantly close-ended questions, and lay definitions of key terms were provided to aid response selection.
Results: Of 301 participants who completed the online survey, 153 (51%) had breast cancer, 100 (33%) had lung cancer, and 48 (16%) had colorectal cancer. Anemia, neutropenia, lymphopenia, and thrombocytopenia were reported by 61%, 59%, 37%, and 34% of participants, respectively. Most participants (79%) reported having received treatment for CIM, and 64% of participants recalled chemotherapy dose modifications as a result of CIM. Although most participants believed their oncologist was aware of the side effects of CIM, and treated them quickly, 30% of participants felt their oncologists did not understand how uncomfortable they were due to the side effects of CIM. Overall, 88% of participants considered CIM to have a moderate or major impact on their lives.
Conclusion: The data highlight that despite the various methods used to address CIM, and the patient-focused approach of oncologists, the real-world impact of CIM on patients is substantial. Improving communication between patients and health care providers may help improve patients' understanding of CIM, and foster shared decision-making in terms of treatment. Additional insights from patients should be obtained to further elucidate the totality of life burden associated with CIM.
Keywords: Anemia; Chemotherapy; Myelosuppression; Neutropenia; Oncology; Online survey; Patient burden; Real-world; Symptom management; Thrombocytopenia.
Plain language summary
This study looked at people with cancer who received chemotherapy and developed a condition where their bone marrow activity was reduced, called myelosuppression. This meant they had fewer red blood cells that carry oxygen around the body, white blood cells that help fight infections, and platelets that help the blood to clot. The researchers wanted to understand how chemotherapy-induced myelosuppression affects peoples’ lives and their cancer treatment, and people’s experiences of treatment for myelosuppression. Overall, 301 people in the USA with breast, lung, or large bowel (colorectal) cancer completed an online survey. They had all received chemotherapy in the last year, and had myelosuppression at least once during their treatment. The survey showed that around 8 in 10 people (79%) had to be treated for myelosuppression, and around 7 in 10 people (73%) felt they received treatment for myelosuppression quickly. Chemotherapy was delayed, reduced, or stopped because of myelosuppression in around 6 in 10 people (64%). Around 3 in 10 people (30%) felt their oncologist did not understand the discomfort that myelosuppression caused them, and around 9 in 10 people (88%) felt that myelosuppression made their quality of life worse. The researchers concluded that because myelosuppression impacts peoples’ lives and their ability to keep receiving chemotherapy to treat their cancer, effective prevention and treatment for this condition are important. Better communication between people and their health care teams could help them to understand how people experience myelosuppression and make plans for treatment together.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7370968/bin/12325_2020_1419_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7370968/bin/12325_2020_1419_Fig2_HTML.gif)
Similar articles
-
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.J Med Econ. 2022 Jan-Dec;25(1):108-118. doi: 10.1080/13696998.2021.2020570. J Med Econ. 2022. PMID: 34927520
-
Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life.Patient Prefer Adherence. 2021 Feb 25;15:453-465. doi: 10.2147/PPA.S292462. eCollection 2021. Patient Prefer Adherence. 2021. PMID: 33658769 Free PMC article.
-
The impact of myelosuppression on quality of life of patients treated with chemotherapy.Future Oncol. 2024 Apr 8:1-16. doi: 10.2217/fon-2023-0513. Online ahead of print. Future Oncol. 2024. PMID: 38587388 Review.
-
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.Curr Oncol Rep. 2022 Dec;24(12):1695-1703. doi: 10.1007/s11912-022-01324-x. Epub 2022 Aug 20. Curr Oncol Rep. 2022. PMID: 35986858 Review.
-
Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial.Cancer. 2015 Nov 1;121(21):3905-13. doi: 10.1002/cncr.29585. Epub 2015 Jul 20. Cancer. 2015. PMID: 26194461 Clinical Trial.
Cited by
-
Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report.Oncol Lett. 2024 Mar 22;27(5):220. doi: 10.3892/ol.2024.14354. eCollection 2024 May. Oncol Lett. 2024. PMID: 38586204 Free PMC article.
-
Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy.Clin Med Insights Oncol. 2024 Jan 5;18:11795549231219497. doi: 10.1177/11795549231219497. eCollection 2024. Clin Med Insights Oncol. 2024. PMID: 38187457 Free PMC article.
-
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.Adv Ther. 2023 Oct;40(10):4189-4215. doi: 10.1007/s12325-023-02601-2. Epub 2023 Jul 25. Adv Ther. 2023. PMID: 37490258 Free PMC article. Review.
-
Nursing Dilemmas in Chemotherapy-Induced Peripheral Neuropathy: A Qualitative Study of a Tertiary Hospital in China.J Pain Res. 2023 Jul 6;16:2299-2308. doi: 10.2147/JPR.S409580. eCollection 2023. J Pain Res. 2023. PMID: 37435154 Free PMC article.
-
The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials.Front Pharmacol. 2023 May 25;14:1157251. doi: 10.3389/fphar.2023.1157251. eCollection 2023. Front Pharmacol. 2023. PMID: 37305548 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous